<br>        Inclusion Criteria:<br><br>          -  Male or female, aged 18 to 30 years, inclusive, with a diagnosis of T1DM with an<br>             interval of 28-56 days between the initial diagnosis and the first dose of study drug.<br>             Documentation of the diagnosis of T1DM (and not just insulin deficiency), including<br>             the date of diagnosis, must be obtained from the diagnosing physician.<br><br>          -  Currently requires insulin for T1DM treatment, or has required insulin therapy for<br>             T1DM (for >=7 days) between the date of diagnosis and the first dose of study drug.<br>             Note: subjects currently taking twice daily commercially available pre-mixed insulin<br>             will not be eligible.<br><br>          -  Positive for at least one of the following autoantibodies typically associated with<br>             T1DM: antibody to glutamic acid decarboxylase (anti-GAD) antibody to protein tyrosine<br>             phosphatase-like protein (anti-IA-2) or an insulin autoantibody (IAA). Please note: A<br>             subject who is positive for IAA and negative for the other autoantibodies will not be<br>             eligible if the subject has been using insulin for a total of >=7days.<br><br>          -  Evidence of residual functioning pancreatic beta-cells as measured by a peak<br>             stimulated C-peptide level > 0.20 nanomoles/litres (nmol/L) during the Screening MMTT<br>             when plasma glucose level is >3.9 mmol/L (70 mg/dL) and <=11.1 mmol/L (200 mg/dL).<br>             Note: the Screening MMTT should not be performed within one week of resolution of a<br>             DKA event.<br><br>          -  Body mass index <=32.0 kilogram/square meters (kg/m^2).<br><br>          -  Female subjects of childbearing potential (i.e., not surgically sterile and/or not<br>             postmenopausal) must be practicing adequate contraception (i.e., meeting one of the<br>             criteria defined below) from at least 14 days prior to the first dose of randomised<br>             study medication until the 12-week post-treatment Follow-up visit : Abstinence from<br>             penile-vaginal intercourse, when this is the female's preferred and usual lifestyle;<br>             Oral Contraceptive, either combined or progestogen alone ; Injectable progestogen;<br>             Implants of etonogestrel or levonorgestrel; Estrogenic vaginal ring; Percutaneous<br>             contraceptive patches; Intrauterine device or intrauterine system that has a failure<br>             rate of less than 1% per year when used consistently and correctly as stated in the<br>             product label; Male partner sterilization prior to the female subject's entry into the<br>             study, and this male is the sole partner for that subject. The information on the male<br>             sterility can come from the site personnel's review of subject's medical records;<br>             medical examination of the subject and/or semen analysis; or interview with the<br>             subject on his medical history.; Male condom combined with a female diaphragm, either<br>             with or without a vaginal spermicide<br><br>          -  Able and willing to provide written informed consent and to comply with all study<br>             procedures.<br><br>        Exclusion Criteria:<br><br>          -  Severe gastroparesis i.e., requiring therapy within 6 months prior to Screening<br><br>          -  History of acute or chronic pancreatitis, or considered clinically at significant risk<br>             of developing pancreatitis, during the course of the study (e.g. due to symptomatic<br>             gallstones, excess alcohol use).<br><br>          -  History of significant gastrointestinal surgery that in the opinion of the<br>             investigator is likely to significantly affect upper gastrointestinal or pancreatic<br>             function (e.g. gastric bypass and banding, antrectomy, Roux-en-Y bypass, gastric<br>             vagotomy, small bowel resection, or surgeries thought to significantly affect upper<br>             gastrointestinal function)<br><br>          -  Personal history or family history of thyroid medullary carcinoma or multiple<br>             endocrine neoplasia type 2 (MEN2)<br><br>          -  History of cancer that has not been in full remission for at least 3 years before<br>             Screening. (A history of squamous cell or basal cell carcinoma of the skin, or treated<br>             cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II is<br>             allowed)<br><br>          -  Fasting triglyceride level >750 milligram/decilitre (mg/dL) at Screening. Subjects may<br>             be re-tested once during screening, and if the value no longer meets the exclusion<br>             criterion, the subject can be randomly assigned to treatment<br><br>          -  Estimated Glomerular Filtration Rate (eGFR) <=30 mL/min/1.73 m^2 (calculated using the<br>             Modification of Diet in Renal Disease (MDRD) formula<br><br>          -  Haemoglobinopathy that may affect proper interpretation of HbA1c<br><br>          -  Alanine aminotransferase (ALT) >2.5 × upper limit of normal (ULN) and bilirubin >1.5 ×<br>             ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and<br>             direct bilirubin <35%)<br><br>          -  Unstable liver disease (as defined by the presence of ascites, encephalopathy,<br>             coagulopathy, hypoalbuminemia, oesophageal or gastric varices or persistent jaundice),<br>             cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or<br>             asymptomatic gallstones). [Chronic stable hepatitis B and C are acceptable if subject<br>             otherwise meets entry criteria and are not on active antiviral treatment (e.g.,<br>             presence of hepatitis B surface antigen or positive hepatitis C test result within 3<br>             months of screening)]<br><br>          -  Any clinically significant co-morbidity or abnormality (including psychiatric<br>             disorder, any other autoimmune endocrinopathy e.g., primary autoimmune hypothyroidism,<br>             hyperadrenalism, coeliac disease etc) that in the opinion of the Investigator, may<br>             pose additional risk in administering study medication or trial participation<br><br>          -  Female subject is pregnant (confirmed by laboratory testing) or lactating<br><br>          -  Known allergy to any GLP-1 analogue, insulin, or excipients of albiglutide<br><br>          -  Treatment with any oral anti-diabetic medication within the prior 30 days or 5 half<br>             lives of that medication, whichever is longer.<br><br>          -  Use of immunosuppressants, intravenous immunoglobulin, oral or systemically injected<br>             glucocorticoids within the 3 months before randomisation or high likelihood of a<br>             requirement for prolonged treatment (>1 week) in the year following randomisation.<br>             However, short courses of oral steroids (single dose or multiple doses for up to 7<br>             days) may be permitted provided these cases are discussed with the medical monitor.<br>             Inhaled, intra-articular, and small quantities of non-potent topical corticosteroids<br>             are allowed<br><br>          -  Receipt of any investigational drug within the 30 days or 5 half-lives, whichever is<br>             longer, before Screening, a history of receipt of an investigational anti-diabetic<br>             drug within the 3 months before randomisation, or receipt of albiglutide in previous<br>             studies.<br>